Goodwin Procter advised Ducentis BioTherapeutics on the deal.Ducentis BioTherapeutics announced its acquisition by Arcutis Biotherapeutics for up to $400 million. Ducentis BioTherapeutics, a portfolio company of LifeArc…
Arcutis Biotherapeutics’ $400 Million Acquisition of Ducentis BioTherapeutics
